These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 16235971)
1. Transparency in economic evaluations. Hill S Pharmacoeconomics; 2005; 23(10):967-9. PubMed ID: 16235971 [No Abstract] [Full Text] [Related]
2. Meandering down the road to transparency. Carswell CI; Paladino JA Pharmacoeconomics; 2008; 26(3):179-80. PubMed ID: 18282012 [No Abstract] [Full Text] [Related]
3. Transparency of economic evaluations of health technologies. Rovira J Pharmacoeconomics; 2008; 26(3):181-3. PubMed ID: 18282013 [No Abstract] [Full Text] [Related]
4. Pharmacoeconomics: integrating economic evaluation into clinical trials. Haycox A; Drummond M; Walley T Br J Clin Pharmacol; 1997 Jun; 43(6):559-62. PubMed ID: 9205814 [No Abstract] [Full Text] [Related]
5. Evaluating the quality of published pharmacoeconomic evaluations. Sanchez LA Hosp Pharm; 1995 Feb; 30(2):146-8, 151-2. PubMed ID: 10140528 [No Abstract] [Full Text] [Related]
6. Assessment of the quality of pharmacoeconomic evaluation literature in China. Zhang F; He X; Xiang W; Li SC J Med Econ; 2017 May; 20(5):510-517. PubMed ID: 28125918 [TBL] [Abstract][Full Text] [Related]
7. Improving drug trials for mild to moderate Alzheimer's disease. Hogan DB Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S97-102. PubMed ID: 17469691 [TBL] [Abstract][Full Text] [Related]
8. Affordability of New Technologies: The Next Frontier. Towse A; Mauskopf JA Value Health; 2018 Mar; 21(3):249-251. PubMed ID: 29566829 [No Abstract] [Full Text] [Related]
9. Is there a need for standardization of methods in economic evaluations of medicine? Rittenhouse BE Med Care; 1996 Dec; 34(12 Suppl):DS13-22. PubMed ID: 8969311 [No Abstract] [Full Text] [Related]
10. Initial development of the Australian Guidelines. Freund DA Med Care; 1996 Dec; 34(12 Suppl):DS211-5. PubMed ID: 8969328 [No Abstract] [Full Text] [Related]
11. Economic assessment within the clinical development program. Schulman KA; Llana T; Yabroff KR Med Care; 1996 Dec; 34(12 Suppl):DS89-95. PubMed ID: 8969317 [No Abstract] [Full Text] [Related]
12. Accumulating evidence for the case of differential discounting. Postma MJ; Parouty M; Westra TA Expert Rev Clin Pharmacol; 2013 Jan; 6(1):1-3. PubMed ID: 23272787 [No Abstract] [Full Text] [Related]
13. Standardization of the economic evaluation of health technologies. European developments. Rovira J Med Care; 1996 Dec; 34(12 Suppl):DS182-8. PubMed ID: 8969325 [No Abstract] [Full Text] [Related]
14. [Educational standards of the Polish Pharmacoeconomic Society]. Czech M; Hermanowski T; Kocić I; Lis J; Nowakowska E; Pol Merkur Lekarski; 2009 Nov; 27(161):400-3. PubMed ID: 19999805 [TBL] [Abstract][Full Text] [Related]
15. [Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations]. Postma MJ; Kwik JJ; Rutten WJ; de Jong-van den Berg LT; Brouwers JR Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1082-7. PubMed ID: 12085558 [TBL] [Abstract][Full Text] [Related]
17. Current efforts in standards development. United States. Power EJ Med Care; 1996 Dec; 34(12 Suppl):DS200-3; discussion DS204-7. PubMed ID: 8969327 [No Abstract] [Full Text] [Related]
18. Medicare's coverage with study participation policy: clinical trials or tribulations? Carnahan SJ Yale J Health Policy Law Ethics; 2007; 7(2):229-72. PubMed ID: 17824405 [No Abstract] [Full Text] [Related]
19. Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach. Lorgelly PK Pharmacoeconomics; 2015 Aug; 33(8):849-55. PubMed ID: 25862464 [TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics and immunotherapy. Berto P Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():12-6. PubMed ID: 18924461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]